G
GlycoVaxyn
Company developing a broad portfolio of bioconjugate vaccines to prevent common bacterial infections using its proprietary glycoprotein technology
About GlycoVaxyn
GlycoVaxyn AG was a Swiss-based biotechnology company that operated in the vaccine development sector, specifically targeting the prevention and treatment of severe bacterial infections. The company was established in 2004 as a spin-off from the Swiss Federal Institute of Technology in Zurich (ETHZ). Its foundation was rooted in the doctoral research of co-founder Michael Wacker, who, alongside Urs Tuor and Michael Stucky, envisioned a new method for creating glyco-conjugate vaccines. Wacker, holding a Ph.D. in microbiology from ETHZ, served as the Chief Scientific Officer, translating his academic work into the company's core technology. In 2008, Philippe Dro, an experienced entrepreneur with a track record in life science transactions, was appointed CEO to steer the company's corporate development.
The company's business model centered on leveraging its proprietary in-vivo glycoengineering and bioconjugation platform. This technology enabled the production of complex conjugate vaccines within simple E. coli bacterial cells, a process designed to be faster, more reliable, and less expensive than traditional chemical conjugation methods. GlycoVaxyn's primary clients and partners were major pharmaceutical companies. The firm's revenue generation strategy involved upfront payments, equity investments, and potential milestone payments and royalties from licensing its vaccine candidates. This was exemplified by strategic collaborations with Janssen Pharmaceuticals and, most notably, GlaxoSmithKline (GSK).
The core of GlycoVaxyn's offering was its biological conjugation platform. This technology synthesizes protein-polysaccharide complexes using recombinant DNA technology inside E. coli, which simplifies the manufacturing process for conjugate vaccines. These vaccines are crucial for preventing bacterial infections like pneumonia and meningitis. The platform's main benefit was its potential to develop vaccines for bacterial pathogens that were previously difficult to target. The company's pipeline included vaccines in development for infections such as Shigellosis, pneumonia, Pseudomonas, and Staphylococcus aureus. The journey culminated in February 2015, when GSK, which had been a minority shareholder since 2012, acquired the remaining shares of GlycoVaxyn for $190 million, bringing the total valuation to $212 million.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2004
- Headquarters
- Zurich, Switzerland
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 57.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Spinout, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2015 | $190M | $190M | GSK | — |
| SERIES B✓Equity / VC | Mar 2009 | $21M | $85M | Index Ventures · Sofinnova Partners · Andera Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for GlycoVaxyn is 310 monthly website visits, down 90.6% over the last three months. GlycoVaxyn's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GlycoVaxyn in the Zurich ecosystem
The GlycoVaxyn office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Index Ventures
Sofinnova Partners
Andera Partners
Other known investors3 additional known investors
ETH Zurich
Grow Cluster Wädenswil
GSK
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about GlycoVaxyn on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GlycoVaxyn’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










